Eclampsia, maternal deaths, and hypertensive diseases of pregnancy and long term maternal health risk by Andersgaard, Alice Beathe
 
 
FACULTY OF HEALTH SCIENCES 
DEPARTMENT OF CLINICAL MEDICINE - OBSTETRICS AND GYNECOLOGY 
Eclampsia, maternal deaths, and hypertensive 




Alice Beathe Andersgaard 
A dissertation for the degree of 
Philosophiae Doctor 



































1. ACKNOWLEDGEMENTS 5 
2. LIST OF PAPERS 7 
3. ABBREVIATIONS 8 
4. BACKGROUND 9 
 4.1 General Introduction 9 
 4.2 Definitions 9 
  Hypertensive diseases of pregnancy 9 
  Maternal death 10 
 4.3 Pre-eclampsia and eclampsia 11 
  Pathogenesis of pre-eclampsia – the underlying multisystem 
syndrome 
11 
  Pathogenesis of eclampsia 14 
  Management of pre-eclampsia 16 
  Management of eclampsia 17 
  Recurrence and long term maternal health risk after pre-
eclampsia 
17 
 4.4 Maternal Mortality 18 
5. AIMS OF THE STUDIES 21 
 5.1 Study I and II 21 
 5.2 Study III 22 
 5.3 Study IV 22 
6. MATERIALS AND METHODS 23 
 6.1 Study I 23 
 6.2 Study II 24 
 6.3 Study III 24 
 6.4 Study IV 24 
7. MAIN RESULTS 25 
 7.1 Study I 25 
 7.2 Study II 26 
 7.3 Study III 27 
 7.4 Study IV 28 
    
8. DISCUSSION 29 
 8.1 Study I and II 29 
 8.2 Study III 31 
 8.3 Study IV 32 
 8.4 Standard of care 32 
 8.5 Methodological considerations and limitation of the present 
study 
34 
 8.6 Perspectives 36 
9. CONCLUSIONS 38 
10. REFERENCES 39 
 APPENDIX  




Financial support has been provided by the Norwegian Medical Research Council, The 





2. LIST OF PAPERS  
This thesis is based on the following papers 
 
Study I 
Andersgaard AB, Herbst A, Johansen M, Ivarsson A, Ingemarsson I, Langhoff-Roos J, 
Henriksen T, Straume B, Øian P. Eclampsia in Scandinavia: incidence, substandard care, and 
potentially preventable cases. Acta Obstet Gynecol Scand 2006;85:929-36. 
 
Study II 
Andersgaard AB, Herbst A, Johansen M, Borgström A, Bille AG, Øian P. 
Follow-Up Interviews after Eclampsia. Gynecol Obstet Invest 2009;67:49-52. 
 
Study III 
Andersgaard AB, Acharya G, Ellisiv Mathiesen, Stein Harald Johnsen, Straume B, Øian P. 
Recurrence and long-term maternal health risks of hypertensive disorders of pregnancy: a 
population based study. Submitted. 
 
Study IV 
Andersgaard AB, Langhoff-Roos J and Øian P. Direct maternal deaths in Norway 1976-1995. 








BMI Body mass index 
BP Blood pressure 
CVD Cardio vascular disease 
CI Confidence interval 
GP general practitioner  
HDL High density lipoprotein 
HELLP Haemolysis, elevated liver enzymes and low platelet count 
ICD 10 International Statistical Classification of Diseases and Related 
Health Problems. Tenth Revision. 
IMT Intima-media thickness 
LDL Low density lipoprotein 
MBRN Medical Birth Registry of Norway  
MgSO4 Magnesium sulphate 
MMR Maternal Mortality Ratio defined as number of maternal deaths 
per 100,000 live births (WHO)  
MRI Magnetic resonance imaging  
NNT Numbers needed to treat  
RCOG Royal College of Obstetricians and Gynaecologists 
SGA Small for gestational age 




4. BACKGROUND  
4.1 General introduction 
Hypertensive diseases of pregnancy are the leading causes of fetal and maternal morbidity and 
mortality. Pre-eclampsia is a multiorgan disease process of unknown aetiology characterized 
by the development of hypertension and proteinuria after 20 weeks of gestation. Delivery is 
the only cure for pre-eclampsia. Decisions regarding the timing and mode of delivery are 
based on a combination of maternal and fetal factors.  
 
Ten percent of women have high blood pressure during pregnancy and pre-eclampsia 
complicates 3-5% of all pregnancies (1). Eclampsia is the occurrence of convulsions in 
association with the signs and symptoms of pre-eclampsia. It is traditionally considered a 
more severe form of pre-eclampsia and complicates nearly one in 2000 pregnancies (2;3).  
 
Pre-eclampsia and cardiovascular diseases share many risk factors and increased risk of 
cardiovascular disease among women with a previous history of pre-eclampsia is well 
described. It is suggested that pregnancy is a screening test for later hypertension and diabetes 
(4). This might reflect a common cause for pre-eclampsia and cardiovascular disease or an 
effect of pre-eclampsia on development of cardiovascular diseases.   
 
Pre-eclampsia is together with thromboembolism, the leading underlying causes of maternal 
death. Maternal death in Europe is a rare event and the maternal mortality ratios (MMR) in 
European countries are low compared to that in developing countries (5-12). Hogan et al 
estimated that there were 342,900 (uncertainty interval 302,100-394,300) maternal deaths 
worldwide in 2008 (6), thus 940 women die from complication in pregnancy or childbirth 
every day. Each death of a mother represents a tragedy and most deaths are avoidable.  
 
4.2 Definitions 
Hypertensive diseases of pregnancy 
The National High Blood Pressure Education Program Working Group on High Blood 
Pressure in Pregnancy, 2000, defined four categories of hypertension in pregnancy: pre-
eclampsia/eclampsia, gestational hypertension, chronic hypertension and pre-eclampsia 
superimposed on chronic hypertension (1).  
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Pre-eclampsia is defined as a pregnancy-specific syndrome observed after the 20th week of 
pregnancy with systolic blood pressure of ≥ 140 mm Hg or diastolic blood pressure of ≥ 90 
mmHg, accompanied by significant proteinuria. Proteinuria is defined as the urinary excretion 
of 0.3g protein or greater in a 24-hour specimen. This will usually correlate with 30mg/dL 
(“1+ dipstick”) or greater in a random urine determination with no evidence of urinary tract 
infection. 
 
Eclampsia is the occurrence of seizure(s) superimposed on pre-eclampsia, during pregnancy 
or in the first 10 days postpartum, that cannot be attributed to other causes.  
 
Gestational hypertension is determined by increased blood pressure of ≥140 / 90 mm Hg in a 
woman normotensive before 20 weeks without proteinuria.  
 
Chronic hypertension is defined as hypertension that is present and observable before 
pregnancy or that is diagnosed before the 20th week of gestation. Hypertension is defined as a 
blood pressure ≥140 mm Hg systolic or ≥ 90 mm Hg diastolic.  
 
Pre-eclampsia superimposed on chronic hypertension is pre-eclampsia that occurs in women 
with chronic hypertension. Distinguishing superimposed pre-eclampsia and worsening 
chronic hypertension is difficult.  
 
In the definition of pre-eclampsia from The National High Blood Pressure Education Program 
Working Group on High Blood Pressure in Pregnancy, 1990, pre-eclampsia included BP 
elevation ≥ 30 mmHg systolic or 15 mmHg diastolic from measured levels prior to the 20th 
gestational week (13).  
 
Maternal death 
The World Health Organization and the tenth revision of the International Classification of Diseases 
(ICD-10), define a maternal death as the death of a woman while pregnant or within 42 days of 
termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause 
related to or aggravated by the pregnancy or its management but not from accidental or incidental 
causes (14). Maternal deaths are subdivided into further groups according to ICD-9/ICD-10.  
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Direct maternal death. Deaths resulting from obstetric complications of the pregnant state 
(pregnancy, labour and puerperium), from interventions, omissions, incorrect treatment, or 
from a chain of events resulting from any of the above. 
 
Indirect maternal death. Deaths resulting from previous existing disease, or disease that 
developed during pregnancy and which was not due to direct obstetric causes, but which was 
aggravated by the physiologic effects of pregnancy. 
 
Late maternal deaths. Deaths occurring between 42 days and one year after legal termination, 
miscarriage or delivery that are due to direct or indirect maternal causes. 
 
Coincidental deaths. Deaths from unrelated causes which happen to occur in pregnancy or the 
puerperium. 
 
4.3 Pre-eclampsia and eclampsia 
Pre-eclampsia is a pregnancy-specific form of hypertension that represents a major health 
problem and affects both fetal and maternal health. Approximately 10% of pre-eclampsia 
occurs before 34 weeks of gestational age and delivery for pre-eclampsia is responsible for 
15% of preterm births in USA (15). The incidence of eclampsia is 5.0/10,000 maternities in 
United Kingdom (UK) and Scandinavia (2;3). In the study from UK nearly one in 50 women 
affected by eclampsia died of the condition as did one in 14 of their offspring.  
 
Pre-eclampsia is an important indicator of an underlying multisystem syndrome and few of the adverse 
effects of pre-eclampsia are directly due to increased blood pressure (16).  
 
Pathogenesis of pre-eclampsia – the underlying multisystem syndrome  
The pathophysiology of pre-eclampsia involves maternal and fetal/placental factors. Redman 
et al argued in 1999 that pre-eclampsia is the extreme end of the range of maternal adaptation 
to pregnancy (17). Pre-eclampsia has been considered a two-stage disease, where the first 
stage involves abnormal placentation and the second the transition to the maternal systemic 






Placental tissue is necessary for development of the disease. In pre-eclampsia the 
cytotrophoblast cells infiltrate the decidual portion of the spiral arteries, but fail to penetrate 
the myometrial segment (19). The spiral arteries fail to develop into large vascular channels 
but remain narrow and a shallow placentation leads to a dysfunctional placenta and this 
combined with atherosis may cause reduced placental perfusion. It is proposed that the poor 
placental perfusion is the cause of pre-eclampsia.  
 
Second stage 
The second stage of pre-eclampsia is described as the transition into a maternal systemic 
disorder. Roberts et al proposed in 1991 that reduced placental perfusion results in the 
production of agent(s) in the placenta, which injures or activates endothelial cells. Smarason et 
al demonstrated that trophoblast products can cause the maternal syndrome of pre-eclampsia 
through endothelial cell damage and endothelial dysfunction through deported microvilli 
(20;21). The resulting endothelial cell dysfunction increases sensitivity to normal endogenous 
pressors, activates the coagulation cascade, and increases vascular permeability (22;23). The 
clinical features of pre-eclampsia can be explained as responses to endothelial dysfunction.  
 
The first model of the two stages was modified by Roberts & Hubel due to new knowledge 
(Figure 1) (18). The reduced placental perfusion is also present in pregnancies with intrauterine 
growth restriction, also without pre-eclampsia. Changes relevant to pre-eclampsia and other 
implantation disorders can be detected in the first trimester, long before the failed vascular 
remodelling. Increased platelet activation and markers of endothelial activation antedate 
clinically evident pre-eclampsia by weeks to months in groups of women who develop the 










Figure 1. The modified 
model of the two stages 
by Roberts & Hubel of 
pre-eclampsia and the 
maternal and fetal 
interactions (18). 
Permission to reprint is 





This model emphasizes that reduced placental perfusion is not sufficient to cause pre-
eclampsia but requires interaction with maternal constitutional factors that may be genetic, 
behavioural or environmental. Earlier the factor(s) released from the placenta has been 
considered a toxin. Roberts & Hubel suggest that what is released may be an appropriate 
signal from the fetal/placental unit to overcome reduced nutrient availability that cannot be 
tolerated by some women who develop pre-eclampsia. Further they proposed that linkage is 
not likely to be by one factor but several, different for different women (18). 
 
The third review of the model was made by Redman and Sargent in 2009 (25). They argue 
that all the inflammatory changes of normal pregnancy are exaggerated in pre-eclampsia and 
that pre-eclampsia not only is an endothelial disease, but the consequence of a wider systemic 
inflammatory response (Figure 2). 
  
Figure 2. The third modified model of 
 pre-eclampsia as the two stage disease 
 including maternal inflammatory stress 
 (25). Permission to reprint is granted 





Early-onset pre-eclampsia represents a considerable additional maternal risk. Von Dadelszen et 
al (26) proposed that gestational age is the most important variable in predicting both maternal 
and perinatal outcomes and subdivide pre-eclampsia into early-onset disease (< 34 + 0 weeks) 
and late onset disease (> 34 + 0 weeks). Vatten et al (27) argued that preterm pre-eclampsia 
represents a placental disease, and that term pre-eclampsia represents a mixture of conditions, 
ranging from mild pre-eclampsia with moderate placental involvement to hypertensive 
conditions without placental dysfunction or maternal reactions to the burden of pregnancy. The 
results of their study indicated that the heterogeneous expression of pre-eclampsia may 
represent separate pathogenetic entities, instead of being one fundamental process expressing 
varying degrees of clinical severity.  
 
Some of the risk factors for pre-eclampsia include; nulliparity and multifetal gestation, past 
obstetrical history of pre-eclampsia, family history of pre-eclampsia, chronic hypertension, 
renal disease, autoimmune disease, antiphospholipid syndromes, obesity, insulin resistance, 
diabetes and thrombophilias (28). The risk factors are not highly predictive.  
 
Pathogenesis of eclampsia  
Eclampsia has been described from ancient time. In an article by Chesley he looks at different 
sources of the historical descriptions of eclampsia (29). Chesley sites Hippocrates (forth 
century BC), Celsus (first century AD) and Mauriceau (17th century). Hippocrates wrote; “It 
proves fatal to a woman in a state of pregnancy, if she is seized with any acute disease”. 
Celsus often mentioned fatal seizures in association with the extraction of dead fetuses, and 
much later Mauriceau had observed that the convulsions became less with delivery and in his 
book in 1694, he recommended prompt termination of pregnancy as the best treatment (29).  
 
The exact cause of seizures in women with eclampsia is unknown. Sheehan and Lynch 
described the neurological findings in autopsies of eclamptic women, most performed within 
1 to 2 hours after death (30). More than 60 percent of the eclamptic patients, who died within 
two days of seizures, had cerebral haemorrhages or ischaemic softening scattered throughout 
the brain. Cerebral venous thrombosis was common in women with postpartum eclampsia. Of 
the cerebral haemorrhages, petechial cortical haemorrhages involving the occipital lobe were 
most common. Sheehan and Lynch explained the cortical petechiae with periods of 
vasoconstriction which cause damage to the cortical tissue and the vessels there. When the 
vasoconstriction passes off some blood escapes through the injured walls of the vessels and 
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produces small haemorrhages. Sheehan and Lynch concluded that the theory of cerebral 
oedema in eclampsia could not be accepted. As opposed to this Zeeman et al examined 27 
women after eclampsia with magnetic resonance imaging (MRI) (31) and found that 25 of 
these 27 women had reversible vasogenic oedema. Six also had areas of cytotoxic oedema 
consistent with cerebral infarction. The cerebral oedema involved the subcortical white and 
adjacent gray matter in the parieto-occipital lobes. The authors conclude that the spectrum of 
cerebral lesions in eclampsia as seen with MRI varies from initially reversible areas of 
vasogenic oedema that may progress to cytotoxic oedema and infarction in up to a fourth of 
women.  
 
The difference in the findings in these two studies might be explained by the fact that the 
study populations were different. Sheehan and Lynch’ study was based on autopsies, while 
Zeeman’s was based on women who survived eclampsia. 
 
These two studies demonstrate the two major hypotheses explaining eclampsia. The first is 
similar to the one described above by Sheehan and Lynch starting with cerebral 
overregulation in response to high systemic blood pressure resulting in vasospasm of cerebral 
arteries and localized ischemia, cytotoxic oedema and infarction. In the second eclampsia is 
explained by loss of autoregulation resulting in hyperperfusion, endothelial damage and 
vasogenic oedema. It has also been questioned whether the cerebral blood flow really is 
altered. The lesions might be a result of extravasations of fluid and protein across disrupted 
endothelium (32).  
 
In an article by Cippola, she supports the findings of Zeeman and describes the major 
cerebrovascular changes in eclampsia to be similar to those for hypertensive encephalopathy, 
including loss of cerebral blood flow autoregulation, hyperperfusion and oedema (33). Her 
summary of similarities between hypertensive encephalopathy and eclampsia includes that 
both can arise from an acute elevation in blood pressure and the findings on MRI. There are 
also similar neurological symptoms with headache, vomiting, cortical blindness and seizures. 
Both in hypertensive encephalopathy and eclampsia the symptoms are reversible after blood 





Management of pre-eclampsia  
Prenatal care, history on risk factors, blood pressure and proteinuria screening are important to 
diagnose pre-eclampsia. Pre-eclampsia is classified according to severity of blood-pressure, 
extent of proteinuria in combination with laboratory tests, the woman’s symptoms and 
gestational age at onset. The treatment of pre-eclampsia is to recognise the disease and find the 
right timing of delivery, to prevent maternal or fetal complications from disease progression.  
 
Pre-eclampsia progresses through a continuum, but the rate of progression differ from one 
woman to another. A woman with pre-eclampsia is evaluated through maternal and fetal 
assessment. The time of delivery will depend on fetal gestational age, fetal status and the 
severity of maternal condition, were the safety of the mother is the main objective of 
management. Most guidelines suggest delivery rather than expectant management for women 
with pre-eclampsia who are ≥37 weeks of gestation with a favourable cervix (34;35). 
 
Severe pre-eclampsia is defined with one or more of the following features; BP ≥ 160/110 
mmHg, proteinuria ≥3.0 g in 24 hours (2+ or 3+ on qualitative examination) or symptoms of 
severe headache, visual disturbances, epigastric pain, platelet count falling below 100 x 109/l, 
increased serum creatinine (>1.2 mg/dL), elevated liver enzymes or HELLP syndrome (36). 
HELLP is a specific subset of signs and symptoms characterized by haemolysis (H), elevated 
liver (EL) enzymes and low platelet (LP) count (1). 
 
Severe pre-eclampsia is regarded an indication for delivery regardless of gestational age, and 
the decision to deliver should be made once the woman is stable. Antihypertensive treatment 
is recommended to prevent cerebrovascular complications with blood pressure ≥160/110 
mmHg (37;38), but antihypertensive drugs do not prevent the progression of pre-eclampsia. 
To prevent eclampsia in patient with pre-eclampsia anticonvulsants are used. C. W. Redman 
writes in the text book “Obstetrics”: “The commonest difficulty is to identify accurately 
which patients are likely to have fits” (39).  
 
In the” The Magpie Trial”, Altman et al randomised 10,441 women with pre-eclampsia to 
magnesium sulphate (MgSO4) versus placebo (40). The risk of eclampsia was more than 
halved amongst women with pre-eclampsia following MgSO4 therapy; the overall numbers 
needed to treat (NNT) was found to be 91, and for a subgroup of women with severe pre-
eclampsia 69. It is still questioned whether it is reasonable to treat 69 women with severe pre-
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eclampsia with MgSO4 therapy to save one woman from suffering eclamptic seizures. Ideally, 
we would seek to find better means of identifying those who are at a high risk of developing 
eclampsia and treat these for the benefit of the mother and her baby. 
 
The Cochrane review by Duley et al included studies on MgSO4 for women with pre-
eclampsia and concluded (41); MgSO4 more than halves the risk of eclampsia, and probably 
reduces the risk of maternal death. It does not improve (40;41) short term outcome for the 
baby. A quarter of women treated with MgSO4 have side effects, particularly flushing.  
 
According to RCOG’s guidelines on “Management of severe pre-eclampsia/eclampsia” 
MgSO4 should be given to women with severe pre-eclampsia once a delivery decision has 
been made and in the immediate postpartum period (37). In the Norwegian guideline (38) 
MgSO4 is recommended based on careful assessment of severity of pre-eclampsia, the 
progression and symptoms like severe headache, epigastric pain, nausea, visual disturbances 
and neurological irritability. 
 
Management of eclampsia 
Initial management of eclampsia includes protecting the airways and minimizing the risk of 
aspiration by placing the patient on her left side. It is also important to prevent trauma from 
falls or violent seizure activity.  
 
MgSO4 is the therapy of choice to control and prevent recurrent seizures (42-45). The 
Norwegian guideline recommends diazepam administrated as rectal gel or intravenous, to 
treat the initial convulsion as an alternative to MgSO4. Treatment with MgSO4 is directed to 
prevent recurrent convulsions (38). Severe hypertension, if present, is treated with 
antihypertensive drugs.  
 
A plan for delivery should be made for women with ante- or intrapartum eclampsia when the 
condition is stabilized.  
 
Recurrence and long term maternal health risk after pre-eclampsia 
The recurrence risk is dependent on the severity and time of onset of pre-eclampsia in former 
pregnancies. Women with severe, very early onset pre-eclampsia seem to have an increased 
risk of pre-eclampsia in future pregnancies (46). The recurrence risk of pre-eclampsia in 
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second pregnancy for women with a singleton pregnancy with pre-eclampsia the first time was 
14.1% (95% CI: 13.6-14.6) in the study by Trogstad et al (47).  
 
In the first follow-up study of women with hypertensive disorders of pregnancy, L.C.Chesley 
(48) followed women with eclampsia for 47 years. He concluded that eclampsia did not cause 
later CVD but linked diabetes and eclampsia.  
 
Today maternal vascular, metabolic, and inflammatory complications in pregnancy such as 
pre-eclampsia, are increasingly linked with an increased risk of CVD in later life (49-53). 
Irgens et al found that the long term risk of death in women with pre-eclampsia and a preterm 
delivery was 2.71-fold higher (95 % CI 1.99 - 3.68) than in women who did not have 
pre-eclampsia and whose pregnancies went to term. The risk of death from cardiovascular 
causes among women with pre-eclampsia and a preterm delivery was 8.12-fold higher (95% CI 
4.31 - 15.33) (54). The systematic review and meta-analysis of McDonald et al found that 
relative to women with uncomplicated pregnancies, women with a history of pre-
eclampsia/eclampsia had an increased risk of subsequent cardiac disease in both the case-
control studies (odds ratio 2.47, 95% CI 1.22-5.01) and the cohort studies (relative risk [RR] 
2.33, 95% CI 1.95-2.78), as well as an increased risk of cerebrovascular disease (RR 2.03, 95% 
CI 1.54-2.67), peripheral arterial disease (RR 1.87, 95% CI 0.94-3.73), and cardiovascular 
mortality (RR 2.29, 95% CI 1.73-3.04)(51). The systematic review and meta-analysis by 
Bellamy et al conclude that a history of pre-eclampsia should be considered when evaluating 
risk of cardiovascular disease in women, and that this association might reflect a common 
cause or an effect of pre-eclampsia on disease development, or both (49). Despite the 
epidemiological evidence of increased risk for hypertension, stroke, coronary artery disease 
and end-stage renal disease (55-58), a clear pathophysiological explanation is not found.  
 
4.4 Maternal mortality 
Women die from a wide range of complications in pregnancy, childbirth or the postpartum 
period. Most of these complications develop because they are pregnant and some because 
pregnancy aggravates an existing disease. The four major killers world-wide are: severe 




The maternal mortality was around year 1900 an important cause of death among young 
women in Norway, and as many as 50% of deaths among women age 15-40 were related to 
pregnancy and birth. It has been a steady decline in the rates until now where less than one of 
ten deaths of women in childbearing age is related to pregnancy and birth (59). The maternal 
mortality ratio (MMR) of direct maternal deaths in the period 1976-1995 was 5.5 per 100,000 
in Norway (60). 
 
Improving maternal health is one of the eight Millennium Development Goals adopted by the 
international community at the United Nations Millennium Summit in year 2000, and the 
target is to reduce MMR by 75% from 1990 to 2015. The MMR in developing countries is 
450 maternal deaths per 100 000 live births versus nine per 100 000 live births in developed 
countries (5;7-11).  
 
Hogan et al assessed levels and trends in maternal mortality in 181 countries 1980-2008 (6), 
and their estimates are showing a decline in numbers of maternal deaths. Their analysis showed 
that although countries can achieve progress in reduction of maternal death, far too many had 
not done so. To reach the Millennium Development Goal they concluded that progress needs to 
be accelerated in many countries. Worldwide they estimated that there were 342,900 
(uncertainty interval 302,100-394,300) maternal deaths in 2008, a decline from 526,300 
(446,400-629,600) in 1980. The global MMR was estimated to be 422 (358-505) per 100,000 
live births in 1980, 320 (272-388) in 1990 and further down to 251 (221-289) in 2008. The 
highest MMR was found in Afghanistan (MMR=1575), the lowest in Italy (MMR= 4). India 
had the largest number of maternal deaths of any country. Six countries account for over half 
of maternal deaths (India, Nigeria, Pakistan, Afghanistan, Ethiopia and the Democratic 
Republic of Congo)(61). 
 
In the study of Hogan et al (6), Norway, together with USA, Canada, Denmark and Austria, 
have an apparent rise in the MMR. They explain this rise with the inclusion of late maternal 
deaths in the ICD 10 and that USA has made a change in their death certificate with a separate 
pregnancy status question. This change might explain the rise, but it also put the focus on the 
difficulty in registration of maternal deaths. The exact number of maternal deaths is hard to 
determine. Even in countries like Norway, where all deaths “need a medical certificate” the 
maternal deaths are frequently missed or misclassified.  
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When the number and cases of deaths are found, the next step is to investigate the deaths to 
identify the causes, the underlying causes of death and the standard of care. “Beyond the 
Numbers” describes five different types of review or audit that can be used in a variety of 
settings, among these are the following two approaches (62): 
 
Confidential enquiries into maternal deaths are a systematic multidisciplinary anonymous 
investigation of all or a representative sample of maternal deaths occurring in an area, 
regional (state) or national level. It identifies the numbers, causes and avoidable factors 
associated with them.  
 
Clinical audit has been described as a quality improvement process that seeks to improve 
patient care and outcomes through systematic review of aspects of the structure, processes and 
outcomes of care against explicit criteria and the subsequent implementation of change. 
Where indicated, changes are implemented at an individual, team or service level and further 
monitoring is used to confirm improvement in healthcare delivery. 
 
United Kingdom has since 1952 had a national professional self-audit of maternal deaths, The 
Confidential Enquiry into Maternal Deaths. The most common cause of direct deaths in the 
Enquiry 2000-2002, was thromboembolism with pre-eclampsia/eclampsia second. The most 
common cause of indirect maternal deaths was psychiatric illness, with suicide as the overall 
leading cause (63). In the Enquiries 2003-2005 thromboembolism was the commonest cause 
of direct deaths, and cardiac disease was the most common indirect cause (64). In the last 
report, the eighth Report of the Confidential Enquiries into Maternal Deaths in the UK (2006-
2008)(65), there has been a significant reduction in the overall maternal death rate from 13.95 
per 100 000 maternities in the triennium 2003-2005 to 11.39 per 100 000 maternities in 2006–
08. Cardiac disease remains the most common cause of indirect maternal deaths. Sepsis is in 
the last triennium the commonest cause of direct maternal deaths in the UK, followed by pre-
eclampsia/eclampsia and thromboembolism. The number of deaths from pre-
eclampsia/eclampsia has not fallen. 
 
In the UK, France and the Netherlands, where confidential inquiries into maternal deaths have 
been performed, 40-70% of the direct deaths are shown to be associated with substandard care 
(63-68). These inquiries both look into the underlying diseases of maternal deaths and evaluate 
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the standard of care. The practicing consultants in obstetrics, the midwives and the general 
practitioners get analyses of avoidable factors and can subsequently implement changes.  
 
5. AIMS OF THE STUDIES 
To improve care we need information of the severe complications of pregnancy, childbirth and 
the puerperium. Through this thesis we focused on two dramatic events; women suffering 
eclampsia and maternal deaths. We wanted to determine the magnitude of the problems, tried 
to assess trends and identify risk groups. Another focus was the follow-up of women with pre-
eclampsia and eclampsia, due to persisting symptoms and increased risk of CVD in later life. 
 
5.1 Study I and II 
In Scandinavian register-based studies, the incidence of eclampsia was found to be among the 
lowest in the world with reported incidences of 1.7-3.3/10,000 maternities (69-72). The 
Medical Birth Registry of Norway (MBRN) reported an incidence of eclampsia of 0.1/1000 
deliveries from 1990 to 1994. In 1995 the incidence increased to 0.3/1000 deliveries and in 
1996 0.4/1000 deliveries, but the incidence was still low compared to other European 
countries.  
 
New guidelines in the management of eclampsia were introduced in 1998, recommending the 
use of MgSO4 as anticonvulsant (73).  
 
We wanted to conduct a survey to determine the incidence of eclampsia in Scandinavia, the 
clinical manifestation, management, current use of anticonvulsants and the outcomes of the 
eclamptic patients and their newborns. The study design included an evaluation of the standard 
of care and a follow-up interview of the women. 
 
Aim of study I 
This prospective study was designed to measure the incidence of eclampsia in Scandinavia 
over a two year period and to audit the clinical care for patients with eclampsia. The study 
aimed to analyse how many cases of eclampsia are potentially preventable by timely 




Aim of study II 
The aim of this study was to assess the prevalence of any self-reported persisting long-term 
symptoms following eclampsia. The working hypothesis was that women with eclampsia 
would be likely to have long-term symptoms or sequelae following the severe condition 
eclampsia represents. 
 
5.2 Study III 
Tromsø IV is a population-based survey for risk factors associated with coronary heart 
disease. The forth survey included questions on former hypertensive disorders of pregnancy. 
We wanted to explore the associations between hypertensive diseases of pregnancy and the 
risk of maternal cardiovascular diseases later in life. To answer the question women reporting 
former pre-eclampsia and non-proteinuric hypertension were compared with women reporting 
normal pregnancies. Parameters like general characteristics and results of the physical 
examinations, current health situation, carotid intima-media thickness (IMT) and plaque in the 
carotid artery, and familiar disposition of coronary heart diseases were compared. The study 
also analysed the recurrence rate for hypertensive complications in subsequent pregnancies. 
 
Aim of study III 
The aims were to investigate the recurrence risk of hypertensive disorders in subsequent 
pregnancies and explore the associations between hypertensive disorders of pregnancy and 
maternal cardiovascular risk factor profile and development of cardiovascular diseases later in 
life. 
 
5.3 Study IV 
The number of maternal deaths is underestimated in most developed countries (7) and the 
exact number of maternal deaths is hard to determine. Information is needed to understand the 
events leading to death.  
 
Aim of study IV 
The aims were to identify and audit direct maternal deaths in Norway that occurred 1976- 
1995, to classify them according to the underlying causes of death and evaluate the standard 
of care and preventability. 
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6. MATERIALS AND METHODS  
6.1 Study I 
The study is a descriptive cohort study of eclampsia in Denmark, Norway and Sweden 
through a two-year period (mid 1998- mid 2000). Regular return letters with requests for 
notification of any possible case of eclampsia were sent to all maternity units in Scandinavia 
at 3-monthly intervals. We received photocopies of the pre-hospital and hospital case records 
for both mother and child. Data were further validated by cross checking cases with cases 
reported to the national birth registers. 
 
Each case was evaluated according to the following predefined criteria for substandard 
medical care: (i) no referral to hospital if signs of pre-eclampsia (hypertension and 
proteinuria) or symptoms, such as intense headache or epigastric pain; (ii) if patients referred 
to the hospital with severe pre-eclampsia did not have their blood pressure measured nor 
blood samples or tests of proteinuria performed; (iii) if patients were not treated with 
antihypertensive drugs despite blood pressure of /160/110 mmHg on repeated measurements; 
(iv) when patients with severe pre-eclampsia and symptoms of imminent eclampsia were not 
delivered by caesarean section or had labour induced within reasonable time; or (v) when 
MgSO4 infusion was not commenced following the first eclamptic fit. A patient case was 
considered as having been treated with substandard care if the case met one or more of the 
above criteria. Cases were categorized as substandard self-care if the woman had not followed 
the recommended antenatal care program, or did not accept hospital admission before 
eclampsia.  
 
Eclampsia was defined as the occurrence of convulsions during pregnancy or in the first 10 
days postpartum together with at least two of the following features within 24 hours after the 
convulsions: pregnancy-induced hypertension; proteinuria (at least 0.3 g/l in a random 
sample); thrombocytopenia (a platelet count of <100x109/l); or an increased plasma aspartate 
aminotransferase concentration (ASAT of ≥ 42 IU/l).  
 
Pregnancy-induced hypertension was defined as a booking diastolic blood pressure of < 90 
mmHg, a maximum diastolic pressure of ≥ 90 mmHg and a diastolic increment of ≥ 25 mmHg 
(5). This definition of hypertension made it possible to compare our findings with the similar 
study made in UK (3). 
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6.2 Study II 
Native speaking women from Study I, who could be traced and consented, were followed up 
by a structured telephone interview between 6 and 24 months after the eclamptic episode. A 
structured questionnaire was used for all patients including both open and closed questions on 
their former obstetric history and persisting sequelae and symptoms at follow-up.  
 
6.3 Study III 
The Tromsø Study is a population-based multipurpose, single-center study with main focus 
on cardiovascular risk factors and disease. All inhabitants in the municipality of Tromsø, aged 
25 or older (born before 1970) were invited to participate in the study, among which 14,293 
were females. The screening consisted of self-administered questionnaires, clinical 
measurements, laboratory tests and ultrasonographic examination of the carotid artery. Risk 
profile for CVD was assessed using anthropometry, BP measurement, laboratory tests and 
ultrasonographic assessment of carotid artery intima-media thickness (IMT) and plaque in the 
carotid artery both linked to risk of CVD (74) and pre-eclampsia (75), was performed. 
 
Parous women who could specify hypertension and/or proteinuria in their pregnancies, were 
included (n=9,974), and divided into four groups; women with pre-eclampsia, with non-
proteinuric hypertension, with normotensive proteinuria and without hypertension and 
proteiuria in their pregnancies. 
 
Pre-eclampsia was in this study not defined according to the ordinary classifications (1). The 
categorization of women in the different groups was based on their answers in the 
questionnaires. They were asked about hypertensive complications in their pregnancies with 
questions like:  
• During pregnancy, have you had high blood pressure and/or proteinuria? 
• If you have had high blood pressure during pregnancy, was it your first pregnancy? 
• If you have had proteinuria during pregnancy, was it your first pregnancy? 
 
6.4 Study IV 
The maternal deaths were identified through the Cause of Death Registry, Statistics Norway 
and the MBRN. During 1976 – 1995, we identified 61 direct maternal deaths. In 51 cases we 
received photocopies of the hospital case records and 45 included autopsy reports. 
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In the study, we categorized the maternal deaths according to the underlying cause, i.e. the 
disease or the complication that started the cascade of events leading to death. This 
categorisation was made based upon the hospital case notes and the results from autopsy 
reports.  
 
The quality of care was evaluated by audit by the authors based on in-depth investigation of 
the case records. Each case was also assessed with reference to its preventability. The deaths 
were categorized as unavoidable, potentially avoidable and avoidable considering the 
treatment, national guidelines and procedures at the time of the study (76). 
 
7. MAIN RESULTS 
7.1 Study I 
The incidence of eclampsia in Scandinavia was 5.0/10,000 maternities. Eighty-six percent had 
a diagnosis of pre-eclampsia before the seizure and nine out of ten had at least one physical 
complaint before the first seizure, severe headache being the most common symptom, 
occurring in two thirds. By audit, 42 % were classified as having received substandard care 
(Table 1). In retrospect nearly half of the cases were found potentially preventable by timely 
intervention, improved medical care and systematic use of prophylactic treatment with 
MgSO4.  
 
Table 1. Cases of eclampsia in Scandinavia in a two year period (1998-2000) and the women 
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Difference in incidence in the three countries is not significant (p = 0.138) 
 
 26 
7.2 Study II 
Of the 210 eclamptic patients, 123 (59%) were followed up by structured telephone 
interviews. The patients were interviewed at a median time interval of eleven months 
following the delivery (range 6-24 months). One-hundred and eight (88%) women had 
attended a postpartum follow-up consultation, 84 (68%) at the hospital and 24 (20%) with 
their general practitioner (GP). Twenty-four women (20%) were on antihypertensive 
medications at discharge from the hospital; seven (6%) were still on medication at the time of 
follow-up. The median time for treatment with antihypertensive medications after discharge 
from the hospital was seven weeks (range 1-92 weeks). At the time of follow-up 51% of the 
women had persistent symptoms (Table 2).  
 
Table 2. Symptoms following eclampsia reported by the patients at the time of telephone 










































































7.3 Study III 
Pre-eclampsia in the first pregnancy increased the risk of recurrence in later pregnancies 5.3 
fold (95% CI 4.3-6.5) compared to a normotensive first pregnancy. A strong association 
between hypertensive disorders of pregnancy and future risk of CVD was demonstrated by 
objective assessment of risk factors that can be potentially modified. Women with a previous 
history of pre-eclampsia or non-proteinuric hypertension had an unfavourable cardiovascular 
risk profile. Hypertension was prevalent in 25% and 28% of them, respectively. We found 
significantly higher plaque prevalence and larger total carotid plaque area in women with 
previous pre-eclampsia and non-proteinuric hypertension compared to the control group. In 
addition the carotid artery intima-media thickness (IMT) was increased in pre-eclamptic 
group (Table 3).  
 
Table 3. Age-adjusted levels of total plaque area and intima-media thickness according to 
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Group I; previous pre-eclampsia, Group II; non-proteinuric hypertension in previous 
pregnancy, Group III; normotensive proteinuria in previous pregnancy, and Group IV; no 
hypertension and no proteinuria in previous pregnancies. Contrast test of variances are made 
between group I and group IV (control group), and group II and Group IV (control group). 
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7.4 Study IV 
The MMR of direct maternal deaths in the period 1976-1995 was 5.5 per 100,000. The 
leading underlying causes of deaths were hypertensive disease of pregnancy and 
thromboembolism. Substandard care was delivered in 21 (21/49) of the cases, and mainly in 
the hospitals (18/21). The substandard care was due to inadequate surveillance and treatment 
of the hypertensive disease, inadequate thromboprophylaxis and complications due to clearly 
inappropriate actions taken by the staff. Among the 45 women who gave birth, 32 were 
delivered by a caesarean, and in 17 of these, the death of the mother was directly ascribed to 
the operation (Table 4).  
 
Table 4. The relation between underlying cause of death in 49 cases and substandard care, 































































































































8. DISCUSSION  
8.1 Study I and II 
In developing countries the incidence of eclampsia varies widely with 6-100 cases per 10.000 
live births (77). In the Western countries the incidence of eclampsia has decreased over the 
past century and is now stabilised with 4-6 per 10.000 live births (3;78;79). The MBRN 
reported a low incidence of eclampsia compared to other European countries, and this low 
incidence might depend on a serious underreporting of eclampsia to MBRN during these 
years. In study I we found the incidence of eclampsia in Scandinavia to be 5.0/10,000 
deliveries (2) and in Norway 5.2/10,000 deliveries, comparable to the incidence in other 
developed countries.  
 
In a study of eclampsia in the Netherlands, from 2004-2006, they found a marked increased 
incidence (6.2 per 10,000 deliveries) compared with other Western European countries (79). 
The incidence of eclampsia has been halved in the UK from 1992 to 2005/2006, from 
4.9/10.000 to 2.75/10,000 maternities, presumably as a result of the widespread use of 
MgSO4, following publication of the Magpie trial (65). 
 
Eclampsia is associated with increased risks of maternal morbidity and mortality. The 
reported maternal mortality after eclampsia in a study from the National Hospital, Norway in 
the period 1959-1978 was 3%. Almost 50% had three or more eclamptic seizures, and one 
third developed severe complications (80). Based on later studies is seems that the outcome 
among women with eclampsia is less severe. In the study by Douglas et al in the UK from 
1992 nearly one in 50 women (1.8%) died, and 35% of all women had at least one major 
complication (3). In our study, including 210 women with eclampsia in Scandinavia (1998-
1999), three women had a cerebrovascular accident (1.4%) and there were no maternal deaths. 
In the study from the Netherlands the case fatality rate was 1 in 74 (1.4%) and 3.3% had a 
cerebrovascular accident (79).  
 
In study I the prodromal symptoms of eclampsia were high-lighted. The subjective symptoms 
like severe headache, visual disturbances and epigastric pain or vomiting, are important when 
diagnosing severe pre-eclampsia and should lead to careful clinical assessment to prevent 
complications. In the interviews 6-24 month after the eclamptic fit many women were still 
overwhelmed by the experience of the intense, frontal headache that preceded eclampsia and 
described it as ‘the most intense pain ever experienced’ and ‘a pain worse than the most 
 30 
intense uterine contractions’. Many women reported having experienced a severe fear of death 
after the eclamptic fit and many had persistent symptoms consistent with post-traumatic stress 
disorder (problems to concentrate, tiredness, restlessness). The information about sequelae for 
a selected group of women with eclampsia is sparse, especially regarding subjective 
symptoms and minor health problems. Our study with follow-up interviews adds new 
information about this group (81). At the time of follow-up, 63 women (51%) had at least one 
persistent symptom; two patients had severe neurological sequelae (hemiparesis and 
dysarthria), 11% had visual disturbances, 22% had problems concentrating or recalling phone 
numbers and messages, 18% reported frequent headaches and 10% had vertigo or balance 
problems. 
 
Chesley followed 270 women surviving eclampsia though a period of more than twenty years, 
with focus on hypertension and hypertensive diseases and genetics (82;83). The Magpie Trial 
was a randomised trial comparing MgSO4 with placebo for pre-eclampsia (42). In a two-year 
follow-up study of these patients (mainly by mail), two thirds of the surviving women in both 
groups reported at least one health problem. Ninety-five of 3,375 women (2.8%) had 
persisting serious morbidity, severe hypertension (2.4%), 8% were still on antihypertensive 
drugs, renal problems (0.4%) or sequelae after stroke (0.1%)(84). In our Scandinavian study, 
6% of women with eclampsia were still on antihypertensive medication at the time of follow-
up and 2% had severe morbidity. The number of women reporting complications or persistent 
symptoms after eclampsia in the Scandinavian countries is lower than reported in the two 
two-year follow-up of the Magpie Trial. The result may be regarded as reassuring according 
to the low frequency of severe neurological sequelae following eclampsia. Since the Magpie 
follow-up addressed women with pre-eclampsia and our study addressed women with 
eclampsia, we had expected to find a higher rate of complications, assuming that eclampsia is 
a more severe form of pre-eclampsia.  
 
Based on the findings in study I and II we suggested a need for routine clinical follow-up of 
patients with eclampsia. Although few women suffer from severe sequelae, many women 
have persisting symptoms indicating a need for follow-up. This is also important due to the 
epidemiological evidence of increased risk for CVD as hypertension, stroke, coronary artery 




8.2 Study III 
In the study of hypertensive disorders of pregnancy and long term maternal health risk the 
women suffering pre-eclampsia and non-proteinuric hypertension had an unfavourable risk 
profile based on history, physical examination, blood tests and carotid artery ultrasound. 
Women with previous history of pre-eclampsia had doubled risk of hypertension and coronary 
artery disease compared to controls. They had carotid plaques more often, had larger total 
carotid plaque area and intima-media thickness compared to controls. We find an association 
between pregnancy-related hypertensive disorders and plaque burden. Compared to early IMT 
changes, plaque formation may represent a later, manifest stage of atherosclerosis and a closer 
relationship to clinical vascular disease 
 
In a systematic review and meta-analysis by Bellamy et al including both retrospective and 
prospective studies, they found an increased risk of cardiovascular disease (49). The relative 
risks for hypertension were 3.70 (95% CI 2.70 - 5.05) after 14.1 years weighted mean follow-
up, for ischaemic heart disease 2.16 (95% CI 1.86 - 2.52) after 11.7 years, for stroke 1.81 
(95% CI 1.45 - 2.27) after 10.4 years, and for venous thromboembolism 1.79 (95% CI 1.37 - 
2.33) after 4.7 years. No increase in risk of any cancer was found. Another systematic review 
and meta-analysis by McDonald et al concludes that women with a history of pre-eclampsia/ 
eclampsia have approximately double the risk of early cardiac, cerebrovascular, and 
peripheral arterial disease, and cardiovascular mortality (51). They suggest further research to 
determine the mechanisms underlying these associations and to identify effective prevention 
strategies. 
 
Although pre-eclampsia and CVD share many of the same constitutional risk factors (85) and 
endothelial dysfunction may persist following a pre-eclamptic pregnancy (53;86-89), no study 
has demonstrated that the risk profile is altered by pre-eclampsia. Furthermore, whether and 
how long the impaired vascular function persists after a pre-eclamptic pregnancy remains 
controversial. A recent study showed that the vascular dysfunction persists 6-24 months 
postpartum only in women with early-onset pre-eclampsia, but not in women who had late-
onset disease (89), whereas the risk of CVD is increased in both. 
 
Hopefully the epidemiological association between hypertensive disorders of pregnancy and 
CVD will result in a routine follow-up of women with hypertensive disorders of pregnancy. 
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The follow-up should primarily encourage the women to modify their life-style to minimise 
avoidable risks and also allow early intervention as medical prophylaxis. 
 
8.3 Study IV 
Even in countries like Norway, where all deaths “need a medical certificate”, maternal deaths 
are frequently missed or misclassified (6;90), and we do not know the exact number of 
maternal deaths in Norway. The death may occur at different places and departments of 
hospitals that do not report routinely to the MBRN. As a consequence of the imprecise figures 
reported, the method applied by WHO in order to estimate the rate of maternal mortality in 
Norway, imply the reported value is multiplied by 1.5 (5). To obtain valid information on all 
direct maternal deaths, we need data from multiple sources, including medical birth registers, 
patient registers, civil registers and cause of death registers (5;11;65;90).  
 
During the work with this study it was difficult to indentify the maternal deaths in Norway, 
and as a consequence only direct maternal deaths are included in the study. Using the medical 
birth registers and cause of death registers we realised that the indirect maternal deaths were 
impossible to identify, and even within the direct maternal deaths the number of identified 
cases might not be correct.  
 
An evaluation of the quality of care found that substandard care was delivered in 21/49 of the 
cases. An important factor associated with direct maternal deaths in Norway 1976-1995, was 
mode of delivery. The estimated fatality rate was 0.27/1000 for caesarean deliveries, and 
0.01/1000 for vaginal deliveries. In addition, more than half of the deaths (17/32) were in the 
audit, judged to be directly attributable to the operation in mothers delivered by caesarean 
section. In the enquiries in UK, “Saving Mothers’ Lives, 2003-2005”, the majority (61%) 
were delivered by caesarean section (64). The steady raise in the caesarean section rate should 
therefore be a matter of concern. 
 
8.4 Standard of care 
It is important that management of pregnancy, labour and delivery meets required standards 
and follows national guidelines. We assume that obstetricians and midwives use evidence-
based guidance for management and decisions made during pregnancy, labour and delivery. 
Contrary to this, it is difficult to implement new guidelines and change or improve physicians 
practice (91). The challenge is illustrated in study I. A new guideline was introduced 
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recommending prevention of recurrent convulsions in eclampsia with MgSO4 (43;73). 
Despite this, substandard care was mainly due to patients not receiving MgSO4 following 
their first seizure. This matter of changing the practice of physicians is commented by John 
Thorp (91): “There is no proof that evidence, no matter how clearly it is formulated and 
spoon-fed to clinicians, will change their practice.”   
 
The standard of care was evaluated through audit in the articles of eclampsia and maternal 
deaths. Substandard care was observed in 42% and 43% of the cases. Studies and enquiries 
from UK, France and the Nederland on maternal mortality and severe morbidity find that 
many women are treated with substandard care and not treated according to the national 
guidelines (63;64;66;67;79;92). In the study of eclampsia in the Netherlands (79), substandard 
care was judged to be present in 83% of the cases. In a study in France they tried to determine 
what factors related to health services that might explain substandard care of severe morbidity 
due to obstetric haemorrhage (92). The lack of a 24-hour on-site anaesthetist at the hospital 
and a low volume of deliveries (<500 births per year) were the factors associated with 
substandard care. Overall, 62% of the cases received appropriate care, 24% received totally 
inadequate care and 14% mixed care.  
 
The Norwegian Board of Health centrally and the Norwegian Board of Health in the counties 
handled in the period 2003–2006, 47 cases within the area of pregnancy- and birth care. In a 
recent study the cases are reviewed (93). Several conditions caused the adverse events but 
they were able to classify the events into four main categories: communication- and 
cooperation failure, uncertain lines of responsibility, lack of qualification, and weaknesses in 
the organisation. The examination of the material disclosed that at least 2/3 of the adverse 
events could be traced back to organisation of the facility and uncertain lines of responsibility 
although the definition of systemic failure is unclear. 
 
In the Confidential Enquiry “Saving mothers lives 2003-2005” (64) the assessors classified 
64% of direct deaths and 40% of indirect deaths as having some degree of substandard care. 
The major concerns in the Enquiries have been lack of inter-professional and/or inter-agency 
communications. There were a number of cases in which crucial clinical information, which 
may have affected the outcome, was not passed from the general practitioner to the midwifery 
or obstetric services at booking or shared between consultants in other specialties, including 
staff in accident and emergency departments and the obstetric team.  
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In the Confidential Enquiry “Saving mothers lives 2006-2009” another aspect is discussed 
(65). A lack of clinical knowledge and skills among some doctors, midwives and other health 
professionals was one of the leading causes of potentially avoidable cases. One of the 
commonest findings was the initial failure by the clinical staff to immediately recognise and 
act on the signs and symptoms of potentially life-threatening conditions. 
 
8.5 Methodological considerations and limitation of the present study 
This thesis includes observational studies trying to identify patterns of practice related to the 
management of eclampsia and maternal deaths. 
 
The study “Eclampsia in Scandinavia” was a prospective study including all women giving 
birth in a two-year period (mid 1998 – mid 2000) in Scandinavia. Notifications of eclampsia 
cases were obtained from all obstetric units at 3 monthly intervals, including 210 women with 
eclampsia. All patient files were reviewed, and systematic audit was carried out to identify 
potentially preventable cases using predefined criteria. One hundred and twenty-three women 
(59%) were followed up with a structured telephone interview, 6-24 months (median 11) after 
their eclamptic fit.  
 
Some limitations of Study II, “Follow-up interviews after eclampsia”, should be noted. First, 
there was no control group. The control group could have been women with normotensive 
pregnancies or with pre-eclampsia without eclampsia. The follow-up rate was only 59%, and 
although we did not find any evidence that the non-interviewed women differed from the 
interviewed subjects, we cannot be certain that the interviewed group is representative of all 
women with eclampsia. Second, the study was based on telephone interviews without any 
clinical investigation and the results reflect the subjective experiences of the women rather 
than objectively registered parameters. Telephone interview was chosen because this was a 
study including all obstetric units in Denmark, Norway and Sweden. Since the present study 
was descriptive and did not follow a case-control study design, it is not possible to draw any 
firm conclusions on the causal relationship between eclampsia and the reported symptoms at 
follow-up.  
 
The management of individual deaths and eclampsia was evaluated by audit by the authors, 
based on in-depth investigation of the case records. Each case was evaluated according to 
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predefined criteria for substandard care. In general, the audit as method can provide evidence 
of where problems may lay and identify areas of required recommendations and 
improvements.  
 
The maternal deaths were also assessed with reference to its preventability. The deaths were 
categorized as unavoidable, potentially avoidable and avoidable considering the treatment, 
national guidelines and procedures of today (38;76). 
 
In the report “Why Mothers Die 2000-2002” (63) the limitation of randomised trials dealing 
with rare events, like many of the causes of maternal death, is discussed. The authors argue 
that randomised trials, unless they are very large, provide little information about rare 
complications of treatments and that safety issues are better illuminated by observational 
studies. Through audit the management is evaluated according to predefined evidence based 
guidelines. They state that treatment options for the rare events will rely on lesser levels of 
evidence and frequently on “expert opinions”. Criterion-based audit has been used in 
obstetrics to improve quality from the midwives/doctors' perspective and in a systematic 
review 95% of studies showed significant improvement in at least one standard measured 
(94). Audits of severe complications and maternal death allow development of strategies to 
prevent morbidity and mortality associated with pregnancy. Since maternal deaths are rare in 
developed countries severe acute maternal morbidity is considered a new indicator of the 
quality of obstetric care and audit can be used to indentify substandard care (95). The best 
result of the audit relates to the action it stimulates in the health system (96), thus the audit 
gives the obstetricians and midwives the possibility to review the complications.  
 
In Study III, “Recurrence and long-term maternal health risks of hypertensive disorders of 
pregnancy: a population based study” there was no strict definition of the level of the blood 
pressure considered pathological during the pregnancy. The occurrence of hypertensive 
diseases in pregnancy is based on self-reporting by women years after their pregnancy (36% > 
50 years old). The recall bias might be a valid concern both concerning maternal-recall of self-






Eclampsia complicates one in 2000 pregnancies in Scandinavia. The exact cause of eclampsia 
is unknown. Pregnancy is associated with significant cardiovascular adaptation of the 
circulation. As pointed out by Cippola (33) it is important to understand how the cerebral 
circulation is altered during gestation and in response to pre-eclampsia and how this might 
contribute to the development of eclampsia. The understanding of the cerebral circulation 
adaption during pregnancy with the endothelial dysfunction and oxidative stress in pre-
eclampsia in combination with loss of cerebral blood flow autoregulation, and the disruption 
of blood-brain barrier might be important to the treatment and prevention of eclampsia (33). 
 
In the follow-up interviews with women 6-24 months after eclampsia, we found the majority 
of women to have persisting symptoms, indicating a need for further clinical investigations of 
the long-term consequences of eclampsia. A case-control study might provide the answer to 
whether symptoms like headaches, depression, tiredness, and failure to concentrate are more 
frequent among women who have suffered from pre-eclampsia or eclampsia than after 
uncomplicated pregnancies.  
 
Most eclamptic convulsions occur in hospitals in women with diagnosed pre-eclampsia. Nine 
out of ten had warning signs or symptoms heralding the seizure. Of the women with 
eclampsia 42% were treated with substandard care. It is important to analyse the factors 
leading to substandard care and identify methods to reduce substandard care. In the 
“Confidential Enquiries into Maternal Deaths in the United Kingdom 2006-2008” the most 
important challenge identified was the need to improve clinical knowledge and skills (65). 
The need for continuous education and training must be taken seriously and every obstetric 
unit would benefit from having an audit on all serious events in the unit and established 
protocols for coping with severe events like eclampsia.  
 
Women who had pre-eclampsia, have an increased risk of cardiovascular diseases in later life. 
If greater awareness of this association could lead to earlier diagnosis and improved 
management, it might be possible to reduce the morbidity and mortality of CVD. Women 
with hypertensive disorders of pregnancy might benefit from counselling and appropriate 
follow-up providing the opportunity for early life-style interventions and primary prevention 
strategies. The findings of the studies of eclampsia and pre-eclampsia and long-time maternal 
health risk both indicate a need for follow-up of women with eclampsia and pre-eclampsia. 
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Hopefully clinical practice is applying the knowledge that has been gained through research 
and implements new guidelines for follow-up of these women.  
 
The main findings in this thesis are based on audit of severe complications in obstetrics. It is 
important to remember that even in Norway the correct numbers of maternal deaths are 
unknown. Hopefully it will be possible to establish a better system for registration and audit 
of all maternal deaths. Through clinical audit with review of patient care against standards, it 
will be possible to improve quality of obstetric care (94). Detailed assessment of individual 
women through audit by the Confidential Enquiry into Maternal Deaths in the United 
Kingdom has been acknowledged as a major contributor to the decline of maternal deaths in 
the UK over the past 50 years (95).  
 
We need a Nordic Confidential Inquiry with recent, not historical data, every two or three 
years in order to survey this rare and very serious outcome. This will offer an alternative to 
the medicolegal processes often pursuing these cases. An open audit performed by health care 
professionals will lead to a quality improvement for the benefit of the women.  
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9. CONCLUSIONS  
The incidence of eclampsia in Scandinavia was 5.0/10,000 maternities. Eclampsia occurred 
mainly in hospital and the majority of women had symptoms heralding the seizure. In 
retrospect, nearly half of the cases were found potentially preventable by timely intervention, 
improved medical care and systematic use of prophylactic treatment with MgSO4. Although 
few women suffer from severe sequelae, many women had persisting symptoms following 
eclampsia. 
 
A strong association between hypertensive disorders of pregnancy and increased risk of 
atherosclerosis and CVD was demonstrated by objective assessment. Previously pre-
eclamptic women had significantly larger carotid artery intima-media thickness and total 
carotid plaque area. 
 
The direct maternal mortality ratio in Norway was 5.5/100,000 births in 1976-1995. A 
majority of the cases was considered potentially avoidable and associated with caesarean 
delivery. 
 
Patient safety and implementation and use of guidelines are important to reduce maternal and 
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111 Varighet av hospitalisering etter kramper (dager) 
112 Lå pasienten på intensivavdelingen 
 
 
113 Maternell død 
0 = Ja 
1 = Nei 
 
114 Tid for maternell død 
0 = Antenatal 
1 = Intra partum 
2 = Post partum 
3 = Usikker 
 
115 Dato for morens død 
116 Årsak til død 
0 = Ukjent 
1 = Cerebrovasc. ulykke 
2 = Lungeemboli 
3 = Blødning 
4 = Sepsis 
5 = Respirasjonssvikt 
6 = Annet (spesifiser). . . . . . . . . . . . . . . . . . . . . . . . .  
117 Obduksjon foretatt 
0 = Nei 
1 = Ja 
Resultat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 






Ble CT tatt 
Spesifiser resultat . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Ja         Nei
          
119 Ble MR tatt 
Spesifiser resultat . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
Ja         Nei
          












Annet (spesifiser) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 




Ja         Nei
          
          
          
          
          
          
           
           
           
          






Utkomme barn 1 
0 = Intrauterin død 
1 = Intrapartumm død 
2 = Nenonatal død (0-7 dager) 
3 = Død senere (< 7 dager) 
4 = Overlevet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
122 Apgar 1 min (angi verdi) 
123 Apgar 5 min (angi verdi) 
124 Kjønn barn 
0 = gutt 
1 = pike 
125 Fødselsvekt (g) 
126 Centile (vekt) ved fødsel 
127 Lengde (cm) 
128 Hodeomkrets (cm) 
129 Tid for barn i intensivavdeling (dager) 




Spesifikk neurologisk utfall 
Retinopati 
Annet (spesifiser) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Ja         Nei
          
          
          
          
          
131 Barnets helstilstand ved 6 måneder (frisk) 
Hvis nei, spesifiser . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ja         Nei
          
 











Annet (spesifiser) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Ja         Nei
          
          
          
          
          
          
          
          
          
          
 
133 Dato for død barn 1 
134 Utkomme tvilling 2 
0 = Intrauterin død 
1 = Intrapartum død 
2 = Neonatal død (0-7 dager) 
3 = Død senere ( 7 dager) 
4 = Overlevet 
135 Apgar 1 min tvilling 2  
136 Apgar 5 min tvilling 2 
137 Kjønn tvilling 2 
0 = gutt 
1 = pike 
138 Fødselsvekt tvilling 2 (g) 
139 Tid for barn i intensivenhet tvilling 2 (dager)  




Spesifikk neurologisk utfall 
Retinopati 
Annet (spesifiser) . . . . . . . . . . . . . . . . . . . . . . . . . 
Ja         Nei
          
          
          
          
          











Annet (spesifiser) . . . . . . . . . . . . . . . . . . . . . . . . 
Ja         Nei
          
          
          
          
          
          
          
          
          
          







Akutt sectio før fødsel 
Akutt sectio under fødsel 
Ja         Nei
          
          
          
          
          
          
          
          
143 Klassifisering av tilfelle 
0 = Klassisk eklampsi 
1 = Eklampsi, men bare hypertensjon 
2 = Eklampsi, men bare proteinuri 
3 = Epilepsi 
4 = Andre årsaker til kramper (hypoglykemi, 
       besvimelse, vasovag.) 







Eventuelt spesifiser . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
Ja         Nei
          
          
          
          
 
MOMENTER TIL INNLEDNING VED TEL. INTERVJU 8- 12 UKER POSTPARTUM 
 
 Presentasjon av oppringer 
 Info. om eklampsi- studie i Norge / Skandinavia 
 Påminnelse om at hun ved fødselen og komplikasjoner til denne ble informert om denne 
studie  
 Nå kontakt for å høre hvordan forløpet har vært for deg og barnet ditt 
 
 
MOMENTER TIL AVSLUTNING VED TEL. INTERVJU 8-12 UKER POSTPARTUM 
 
 Informasjon og forespørsel om å få ringe igjen når barnet er 6 mnd. 
 
 
MOMENTER TIL INNLEDNING VED TEL. INTERVJU 6MÅNDER POSTPARTUM 
 
 Presentasjon av oppringer 
 Påminnelse om eklampsi studie og forrige samtale 
 Nå på nytt kontakt for å høre forløpet videre for deg og barnet ditt 
 
 
MOMENTER TIL AVSLUTNING VED TEL. INTERVJU 6MÅNDER POSTPARTUM 
 
 Forespørsel om å ta blodprøve og informasjon om denne, blant annet for å forsøke å finne 
fellestrekk i enkelte blodverdier for kvinner med eklampsi  
 Avtale praktisk gjennomføring med sending av rekvisisjon og hvordan prøven skal tas 
(fastende).  Blodprøve tas ved legekontoret hjemme hos kvinnen 
REGISTRERINGSSKJEMA  EKLAMPSI 
 
 
TELEFONINTERVJU ETTER 8 – 12 UKER 
 
 
1. Studie nr.       -------- 
 
2. Tel.nummer:    ____________ 
 
3. Dato for samtale:_______________ 
 






5. Svangerskapskontroller gjennom ført hos: 
 Ingen    ____ 
Allmennpraktiker  ____ 
 Spesialist   ____ 
 Allmennpraktiker/ jordmor _____ 
 Annet (spesifiser)  _____     (……………………………………) 
 
6. Brukte du noen form for jern-preparater under svangerskapet?       J/N 
 Type preparat:………………………. 
  
 Varighet av behandling  (uker / dager )     ____/_____ 
 
7. Brukte du noen form for antihypertensiva i svangerskapet?  J/N 
 Type preparat:………………………. 
 
    Når ble dette evt. seponert? 
 Svangerskapsuke:……… 




OPPFØLGING, BEHANDLING OG KONTROLLER ETTER EKLAMPSI 
 
8. Antall kontakter med allmennlege etter fødsel   -------- 
 
9. Har du vært til vanlig etterkontroll etter fødsel?    J / N 
 
10. Evt. påviste funn du kjenner til fra disse kontrollene: 
  1 - Ingen       J / N 
  2 - Forhøyet BT      J / N 
  3 - Nevrologiske utfall     J / N 
  4 - Annet        J / N 
  Spesifiser........................................... 
 
11. Bruker du noen medisiner nå? 
  1 - Ingen       J / N 
  2 - Antihypertensiva      J / N 
   Spesifiser type:.................................. 
  3 - Antidepressiva      J / N 
   Spesifiser type:.................................. 
  4 - Andre medikamenter     J / N  




SYMPTOMER OG KOMPLIKASJONER FØR OG ETTER EKLAMPSI 
 
12. Husker du om du hadde noen av følgende symptomer før du fikk kramper på sykehuset? 
  1 - Ingen       J / N 
  2 - Hodepine       J / N 
  3 - Synsforstyrrelser      J / N 
  4 - Epigastrie / hø. costalbuesmerter    J / N 
  5 - Irritabilitet / irritasjon / uro    J / N 
  6 - Annet        J / N 
   Spesifiser:............................................. 
 
 
13. Har du hatt noen av disse symptomene i tiden etter krampene? 
  1 - Ingen       J / N 
  2 - Hodepine       J / N 
  3 - Synsforstyrrelser      J / N 
  4 - Epigastrie / hø. costalbuesmerter    J / N 
  5 - Irritabilitet / irritasjon / uro    J / N 
  6-  Svimmelhet      J / N 
  7 – Konsentrasjonsvansker     J / N 
  8 – Bevegelses /gangvansker     J / N 
9 - Annet        J / N  
   Spesifiser:............................................. 
 
 
14. Er noen av symptomene fortsatt til stede? 
  1 - Ingen      J / N 
  2 - Hodepine      J / N 
  3 - Synsforstyrrelser     J / N 
  4 - Epigastrie / hø. costalbuesmerter   J / N 
  5 - Irritabilitet / irritasjon / uro   J / N 
  6-  Svimmelhet      J / N 
  7 – Konsentrasjonsvansker    J / N 
  8 – Bevegelses /gangvansker    J / N 
9 - Annet       J / N   
  Spesifiser:............................................. 
 
 
15.  Har det vært andre komplikasjoner i forløpet etter fødselen og eklampsien? 
  1 - Ingen      J / N 
  2 - UVI      J / N 
  3 - lungeinfeksjon     J / N 
  4 - DVT      J / N 
  5 - Lungeemboli     J / N  
  6 - Hjerneblødning / cerebral trombose  J / N 
  7 - Synsutfall      J / N 
  8 - Svikt i nyrefunksjonen    J / N 
  9 - Feber      J / N 
  10  Sårinfeksjon     J / N 
  11  Hukommelsestap     J / N 
  12  Nevrologiske utfall    J / N 
  13  Depresjon      J / N 
  14  Psykose      J / N 
  15  Annet      J / N 






16.  Ble barnet utskrevet fra sykehuset samtidig med deg?    J / N 
 
17.  Barnet fortsatt inneliggende i sykehus      J / N 
 
18.  Ble ditt opphold på sykehuset forlenget på grunn av. barnets tilstand  J / N 
 
19.  Lå barnet noen gang på barneavdeling.      J / N 
 
20.  Antall dager barnet var på barneavdeling.                                                       ------- 
 
21.  Har barnet vært til vanlig 6 ukers kontroll?     J / N 
  Evt. bemerkninger ved undersøkelse av barnet  
  ved denne kontrollen:  ....................................................... 
 
22. Opplever dere barnet som friskt?       J / N 
  Om nei, spesifiser mor bemerkninger om avvik:............... 
  ........................................................................................... 
23. Er barnet under utredning hos barnelege / allmennpraktiker?   J / N 
  Om ja; spesifiser for hva:................................................... 
  ........................................................................................... 
24. Ernæring av barnet nå: 
  1 - Ammer    J / N 
  2 - delvis amming   J / N 
  3 - Morsmelk tillegg     J / N 
 
25. Barnets vekt ved 6 uker:   _________ 
 
REGISTRERINGSSKJEMA  EKLAMPSI 
 
 
TELEFONINTERVJU ETTER 6 MÅNEDER 
 
 
1.  Studienr.       -------- 
 
2.  Tel.nummer ___________ 
    
3.  Dato for samtale: ___________ 
 




Oppfølging, behandling og kontroller etter eklampsi 
 
5.  Antall konsultasjoner ved sykehuset etter fødsel   -------- 
 
6. Antall kontakter med allmennlege etter fødsel   -------- 
 
7.  Evt. påviste funn du kjenner til fra disse kontrollene: 
  1 - Ingen      J / N 
  2 - Forhøyet BT     J / N 
  3 – Siste målte BT:   _____/_______ 
        ca.dato for denne målingen:________ 
   
       Proteinuri J/N 
   Om ja tidspunkt for siste kontroll  __________ 
   
3 – Nevrologiske utfall    J / N 
  4 – Annet       J / N 
   Spesifiser…........................................ 
 
8. Bruker du noen medisiner nå? 
  1 – Ingen      J / N 
  2 – Antihypertensiva     J / N 
   Spesifiser type:…............................... 
   Evt. når seponert om tidl. brukt etter fødsel _____________ 
  3 – Antidepressiva     J / N 
   Spesifiser type:…............................... 
  4 – Andre medikamenter    J / N  
   Spesifiser type:…............................... 
 
 
SYMPTOMER OG KOMPLIKASJONER  EKLAMPSI 
 
 
9. Er noen av symptomene fortsatt tilstede? 
  1 – Ingen      J / N 
  2 – Hodepine      J / N 
  3 – Synsforstyrrelser     J / N 
  4 – Epigastrie / hø. kostalbuesmerter   J / N 
  5 – Irritabilitet / irritasjon / uro   J / N 
  6-  Svimmelhet     J / N 
  7 – Konsentrasjonsvansker    J / N 
  8 – Bevegelses /gangvansker    J / N 
9 - Annet       J / N   
  Spesifiser:............................................. 
 
 
10.Har noen av følgende  komplikasjoner oppstått i forløpet etter fødselen og eklampsien? 
  1 – Ingen     J / N 
  2 – UVI     J / N 
  3 – lungeinfeksjon    J / N 
  4 – DVT     J / N 
  5 – Lungeemboli    J / N  
  6 – Hjerneblødning / cerebral trombose J / N 
  7 – Synsutfall     J / N 
  8 – Svikt i nyrefunksjonen   J / N 
  9 – Feber     J / N 
  10  Sårinfeksjon    J / N 
  11  Hukommelsestap    J / N 
  12  Nevrologiske utfall   J / N 
  13  Depresjon     J / N 
  14  Psykose     J / N 
  15  Annet     J / N 





11.  Har du vært til vanlige kontroller på helsestasjonen med barnet?  J / N 
  Evt. bemerkninger ved undersøkelse av barnet  
  ved disse kontrollene:  ….................................................... 
 
12. Opplever dere barnet som friskt?       J / N 
  Om nei, spesifiser mor bemerkninger om avvik:…............ 
  …........................................................................................ 
 
13. Utvikler barnet seg normalt synes du?      J / N 
 
14. Har barnelege/allmennpraktiker /helsesøster sagt noe om avvik i barnest utvikling? J/N 
  Om ja spesifiser…………………………………………. 
  ………………………………………………………….. 
 
15. Er barnet under utredning hos barnelege / allmennpraktiker?   J / N 
  Om ja; spesifiser for hva:…................................................ 
  …........................................................................................ 
 
16. Siste vekt av barnet :  __________ 
 
Dato for vektmåling:  __________ 
 
Barnets alder ved veiingen: __________ 
 
17.  Amming nå    J/N 
 
18. Er menstruasjonen kommet tilbake?   J/N 
  




OM EGEN HELSE FØR DETTE SVANGERSKAPET  / FØDSELEN 
 
19. Ved evt. tidligere svangerskap, var det noen av følgende komplikasjoner i dette? 
 Høyt blodtrykk  J/N 
 Preeklampsi   J/N 
 Glukosuri   J/N 
 Vekstavvik hos barnet J/N 
 
20.Har du tidligere hatt tromboembolisk sykdom?  J/N 
  
 Om ja spesifiser:………………………………… 
  ……………………………………………. 
 
21. Har noen i din familie hatt tromboembolisksykdom? J/N 
  (mor/ far/ søsken før 60 års alder) 
   
  Om ja spesifiser hvem og type sykdom……….. 
  …………………………………………………. 
  
22. Har noen i din familie behandlingstrengende hypertensjon før 60-års-alder?  J / N 
  
 Om ja spesifiser hvem og evt. alder ved debut:… 
  ………………………………………………….. 
 
23. Har noen i din familie hatt hjerteinfarkt før de ble 60 år? J / N 
  
 Om ja spesifiser hvem og evt. alder ved debut:… 




24. Har du tidligere fått påvist for høyt blodtrykk?  J/N 
 
 Grenseblodtrykk…………J/N 
 Hypertoni (ubehandlet)….J/N 
 Hypertoni, med.behandlet J/N 
 




25. Har du fått påvist kronisk nyresykdom  før dette svangerskapet? J/N 
 
 Evt. spesifiser:………………………………………………………………….. 
 
26. Lider du av andre kroniske sykdommer?   J/N 
 
 Evt. ja spesifiser:……………………………………………………………….. 
 
27. Vet du om noen i din familie har hatt  
  Eklampsi:  J / N 
  Om ja hvem ( mor, søster) ……………………. 
Preeklampsi  J / N 
  Om ja hvem ( mor, søsken)……………………. 
 




MANGLER I TIDLIGERE UTFYLT SKJEMA 
 
 
Før avslutning be  kvinnen om manglende opplysninger i tidligere utfylte skjema. 
 
 
Informasjon om blodprøvetaking og praktiske aspekter ved dette. 
 1
PROSJEKT: MATERNELLE DØDSFALL 
 




Hypertensjon     Ja     Nei    
Evt. beskriv (behandling etc) …………………………………………………………………... 
 




















Tromboemboli    Ja     Nei   













Antall svangerskap     
Antall aborter    
Antall fødsler    







Siste menstruasjon …………………………Syklus: ……………./…………… 
Termin Naegle    
Termin UL      
Antall svangerskapskontroller:  
Siste svangerskapskontroll (dato)  
Fødselsdato     
Antall svangerskapsuker   
Fødselsvekt (g)    




Perinatalt dødsfall   Ja     Nei    
Intrauterin død   Ja     Nei     
Neonatal død    Ja     Nei    
Antall dager etter fødsel   
Årsak.…………………………………………………………………………………………… 








Spontan fødsel   Ja     Nei   
Indusert fødsel   Ja     Nei   
Indikasjon..……………………………………………………………………………………… 
 
Sectio     Ja     Nei   
Akutt     Ja     Nei   
Indikasjon..……………………………………………………………………………………… 
 
Elektiv    Ja     Nei   
Indikasjon..……………………………………………………………………………………… 
 
Tang     Ja     Nei   
Vakum    Ja     Nei   
Indikasjon.……………………………………………………………………………………… 
 
Sete     Ja     Nei   
Indikasjon……………………………………………………………………………………….. 
 






KOMPLIKASJON I AKTUELT SVANGERSKAP 
 
Hypertensjon    Ja     Nei   
Preeklampsi    Ja     Nei   
Eklampsi    Ja     Nei   
HELLP    Ja     Nei   
Tromboemboli   Ja     Nei   
Blødning    Ja     Nei   
Uterusruptur    Ja     Nei   
Amnionvæske emboli  Ja     Nei   
Anestesikomplikasjon  Ja     Nei   
Sepsis     Ja     Nei   









Dato   
 
Klinisk diagnose .……………………………………………………………………………….. 
Obduksjon    Ja     Nei   
Diagnose.………………………………………………………………………………………. 
 










Under graviditet    Ja    Nei   
Under fødsel     Ja    Nei   
Postpartum (<42 dager)   Ja    Nei   




Sykehus     Ja    Nei   
Fødestue     Ja    Nei   
Hjemme     Ja    Nei   




KATEGORISERING AV DØDSFALL 
 
















VURDERING AV BEHANDLING 
 
Adekvat     Ja    Nei   
Substandard     Ja    Nei   









VURDERING AV FORLØP TOTALT 
 
Uunngåelig (unavoidable)   Ja    Nei   
Mulig unngåelig (potentially avoidable) Ja    Nei   
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